1. Purdue joining pharma’s top settlement list alongside Merck, GSK, and Pfizer — Biosimilars running into more roadblocks in the US — Big Pharma companies pay for exclusive access to UK genetic data — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Arestin sales falling just like Valeant's stock

Discussion in 'Orapharma' started by anonymous, Apr 5, 2017 at 8:25 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    We are finally feeling the pain of being under Valeant who only cares about the mighty dollar and only profiting for the sake of trying to save their ass. Sales are down across the country and offices are finally saying enough is enough. They are tired of pharma greed and looking at eliminating Arestin all together. It is sad that the only reason they are eliminating it is because OraPharma has based their business model off insurance coverage and greed and not the customer or the patient. Insurance is now failing and now we are in a place I warned about years ago, but sadly wasn't allowed to speak my ideas or thoughts. Burning our customers is at a point of no return. I give it a year till we are sadly in a catalog and put on a shelf next to periochip.
     
  2. anonymous

    anonymous Guest

    Well thank goodness we have 3 other solid products in our bag!
     
  3. anonymous

    anonymous Guest

    I'm going to not work and stay home and just watch this thing burn to the ground just like Matt. I guess once in awhile Ill shoot an email and make it look like I'm working. You know talk about seeking out insurance coverage and saying its normal to miss my number by 60% blah blah blah.
     
  4. anonymous

    anonymous Guest

     
  5. anonymous

    anonymous Guest